WuXi Biologics (Cayman) Inc at JPMorgan Healthcare Conference Transcript
Hello. Hi, good morning, everyone. Welcome to the 42nd JPMorgan Healthcare Conference. Next, we are pleased to introduce the CEO of WuXi Biologics,
Chris Chen, to stage to give us a presentation on the company. Welcome.
()-
Thank you, Li Ning. It's really my pleasure to give everyone an update. So as everyone know, 2023 is a very interesting year. But every time I come to JPMorgan, I actually want to reflect what our industry is facing and what are the trends that's coming to our industry. So BioPlan, some of you know BioPlan is industry consulting. Every year, they collect the data from 200, 300 companies, and they predict what are the trends for our industry. So this is -- they come up with a big three that's relevant to WuXi Bio, and they mentioned top 10 trends basically cell and gene therapy was going there and qualified staff, FDA standard, and all that.
So three trends are relevant to WuXi. I highlighted them here. Oh, sorry, I already go direct
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
